Byooviz

Generic name: Ranibizumab (ophthalmic)
Dosage form: intravitreal injection
Drug class: Anti-angiogenic ophthalmic agents

Usage of Byooviz

Byoovizis a prescription eye injection is used to treat types of macular degeneration, macular edema and myopic choroidal neovascularization. Byooviz is vascular endothelial growth factor (VEGF) inhibitor that works by keeping new blood vessels from forming under the retina (a sensory membrane that lines the inside of the eye). Byooviz (ranibizumab-nuna) is from the class of medicines called anti-angiogenic ophthalmic medications.

Byooviz is an injection delivered into the vitreous humor of the eye (intravitreal) and is usually given once a month.

Byooviz is an interchangeable biosimilar to Lucentis (ranibizumab injection) that was originally approved by the FDA on September 20, 2021, and became an interchangeable medicine on October 3, 2023.

Byooviz is FDA approved to treat:

neovascular (wet) age-related macular degeneration (nAMD) a leading cause of vision loss and blindness for people aged 65 years and older

macular edema following retinal vein occlusion (RVO), this is fluid build-up due to blockage of veins in the retina.

myopic choroidal neovascularization (mCNV), a vision-threatening complication of nearsightedness.

Byooviz side effects

Common Byooviz side effects may include:

eye pain or irritation;

feeling like something is in your eye;

itchy or watery eyes;

dry eyes, puffy eyelids;

blurred vision;

sinus pain, sore throat, cough; or

nausea.

Byooviz may cause serious side effects.

Get emergency medical help if you have signs of an allergic reaction to Byooviz including hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

eye pain or redness, swelling around your eyes;

blurred vision, tunnel vision, eye pain, or seeing halos around lights;

increased sensitivity to light;

discharge or bleeding from the eye;

seeing flashes of light or "floaters" in your vision;

sudden numbness or weakness (especially on one side of the body); or

sudden severe headache, problems with speech or balance.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Byooviz

You should not receive Byooviz if you are allergic to ranibizumab or if you have any type of infection in or around your eyes. To make sure this medicine is safe for you, tell your doctor if you have ever had:

glaucoma; or

a history of blood clots or stroke.

Pregnancy

It is not known Byooviz will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

Breastfeeding

It is not known whether Byooviz passes into breast milk or if it could affect the nursing baby. Tell your doctor if you are breast-feeding.

Relate drugs

How to use Byooviz

Usual Byooviz dosing information

Neovascular (Wet) Age-Related Macular Degeneration (AMD): 0.5 mg by intravitreal injection once a month (approximately 28 days). Comment:

Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment.

Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Patients should be assessed regularly.

Macular Edema Following Retinal Vein Occlusion (RVO): 0.5 mg by intravitreal injection once a month (approximately 28 days).

Myopic Choroidal Neovascularization (mCNV): 0.5 mg by intravitreal injection initially once a month (approximately 28 days) for up to 3 months. Patients may be retreated if needed.

Warnings

Call your doctor at once if you have sudden vision problems, eye pain or redness, or if your eyes are more sensitive to light.

The timing of your monthly injections is very important for this medication to be effective.

What other drugs will affect Byooviz

Other drugs may interact with ranibizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.

Popular FAQ

A biosimilar is a biological product that is similar to a reference biologic (usually the original product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. As an example, the biosimilar Amjevita (adalimumab-atto) was approved as the first biosimilar to Humira (adalimumab). Continue reading

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.